Asset profile
VK2735
Peptide
Evidence outlook · registrational
Obesity: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2027-07-01.
NCT06828055: The study randomized 280 participants to six VK2735 dose groups or placebo and masked participants, care providers, and investigators. Its primary endpoint was the clinical weight-management outcome of percent change in body weight after 13 weeks, but results are not posted, so whether the endpoint was met is unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (2)
July 2027 (2)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchWhat to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.